Outlook Therapeutics Reports Results for Third Quarter Fiscal Year 2025

Published on August 15, 2025
ISELIN, N.J.—Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, yesterday reported financial results for the third quarter of fiscal year 2025 and provided a corporate update. For the fiscal third quarter ended June 30, 2025, Outlook Therapeutics reported a net loss of $20.2 million and $1.5 million of revenue. Revenue consisted of the initial sales into Germany and the U.K. for Lytenava, where title to the product was transferred to the distributor, the company noted.
Continue reading on website
Other news

Dental and vision services for veterans in Medicare Advantage under the microscope

August 14, 2025
Optometry Times delivers clinical news, practice insights, and research updates by optometrists for optometrists to advance care and patient outcomes.

Study demonstrates Lumenis's DMSt effectivity in addressing lower lid laxity, improving blinking quality

August 15, 2025
The study explored the use of DMSt, used in OptiLIFT, in enhancing eyelid muscle function, improving blink dynamics, and consequently alleviating dry eye symptoms.